Mycoplasma Testing Market Benefits from Growing Demand for Biologics

The global mycoplasma testing market is expected to witness significant growth over the coming years, with market value projected to increase from US$ 1.89 Bn in 2025 to US$ 4.52 Bn by 2032. The market is anticipated to expand at a CAGR of 11.5% during the forecast period from 2025 to 2032, supported by growing investments in biopharmaceutical manufacturing, cell and gene therapy development, and increasingly stringent regulatory requirements governing product safety and quality assurance.

Mycoplasma contamination remains one of the most persistent challenges in biological research and pharmaceutical production. These microscopic bacteria can infiltrate cell cultures without visible signs of contamination, affecting cell growth, metabolism, gene expression, and overall product quality. Consequently, mycoplasma testing has become a critical component of quality control protocols across pharmaceutical companies, biotechnology firms, research laboratories, cell banks, and contract research organizations.

As the global life sciences industry continues to expand, the importance of robust contamination detection systems is becoming increasingly evident. Manufacturers are prioritizing advanced testing technologies to ensure regulatory compliance, maintain product integrity, and reduce the risk of costly production delays. The growing complexity of biologics and advanced therapies is further increasing the need for highly sensitive and reliable mycoplasma detection methods.

For More Industry Insights Read: https://www.persistencemarketresearch.com/market-research/mycoplasma-testing-market.asp

Expanding Biopharmaceutical Manufacturing Fuels Market Growth

The rapid growth of biologics manufacturing is emerging as one of the most influential factors supporting market expansion. Pharmaceutical companies are investing heavily in monoclonal antibodies, recombinant proteins, vaccines, and other biologic products that require extensive cell culture processes during development and production.

Since mycoplasma contamination can compromise product safety and efficacy, manufacturers are implementing rigorous testing procedures throughout the production lifecycle. Regulatory authorities worldwide continue to strengthen guidelines related to contamination monitoring, encouraging broader adoption of validated mycoplasma testing solutions. As biologics gain greater prominence within the healthcare sector, demand for advanced testing services and products is expected to rise steadily.

PCR Technologies Strengthen Their Position in Modern Testing Workflows

Technological advancements are transforming the mycoplasma testing landscape, with PCR-based methods becoming increasingly popular among end users. Polymerase Chain Reaction technologies provide rapid, highly sensitive, and accurate detection capabilities compared to conventional microbial culture methods.

Traditional culture-based techniques often require extended testing periods, while PCR-based solutions can deliver results within significantly shorter timeframes. This advantage is particularly valuable in commercial manufacturing environments where operational efficiency and faster product release timelines are essential.

The integration of automation, digital laboratory systems, and high-throughput analytical platforms is also improving testing accuracy and workflow efficiency. As laboratories seek faster and more reliable contamination detection methods, adoption of advanced molecular testing technologies is expected to accelerate throughout the forecast period.

Cell and Gene Therapy Development Creates Significant Opportunities

The growing commercialization of cell and gene therapies is creating substantial opportunities for market participants. These advanced therapeutic products rely on highly controlled manufacturing environments where contamination prevention is a top priority.

Cell therapy developers, regenerative medicine companies, and gene therapy manufacturers require comprehensive quality assurance programs to meet strict regulatory standards. Mycoplasma testing plays a critical role in ensuring the safety and effectiveness of these therapies before they reach patients.

The expansion of personalized medicine initiatives worldwide is expected to further strengthen demand for contamination testing solutions. Increasing research activity involving stem cells, engineered tissues, and gene-modified therapies is likely to generate long-term growth opportunities for testing providers and technology developers.

Regional Markets Continue to Expand Amid Rising Biotechnology Investments

North America is expected to maintain its leadership position in the global mycoplasma testing market due to the presence of a well-established biotechnology ecosystem, advanced pharmaceutical manufacturing infrastructure, and strong regulatory oversight. The region continues to benefit from significant investments in biologics development and clinical research activities.

Europe also represents a major market, supported by increasing research funding, growing adoption of advanced biologics, and a strong focus on regulatory compliance. Pharmaceutical manufacturers across the region are investing in sophisticated quality assurance systems to meet evolving industry standards.

Meanwhile, East Asia and South Asia & Oceania are emerging as high-growth markets due to expanding biotechnology sectors, rising pharmaceutical production capacity, and increasing investments in life sciences innovation. Government support for biotechnology research and growing participation in global biopharmaceutical supply chains are expected to accelerate market growth across these regions.

Competitive Landscape Focuses on Innovation and Strategic Partnerships

The competitive landscape of the mycoplasma testing market is characterized by continuous innovation, strategic collaborations, and product development initiatives. Leading companies are focusing on enhancing assay sensitivity, improving testing speed, and expanding service portfolios to meet evolving customer requirements.

Market participants are also investing in automation technologies and integrated testing platforms that simplify laboratory workflows while ensuring regulatory compliance. Strategic partnerships between testing providers, pharmaceutical manufacturers, and research organizations are expected to play an important role in driving future market development.

Companies Covered in the Mycoplasma Testing Market

• Thermo Fisher Scientific, Inc.
• Lonza Group AG
• Merck KGaA
• Charles River Laboratories International, Inc.
• PromoCell GmbH
• American Type Culture Collection
• Asahi Kasei Medical Co., Ltd
• Sartorius AG
• InvivoGen
• Eurofins Scientific
• ATCC (American Type Culture Collection)

Market Segmentation

By Technology

• PCR
• ELISA
• Direct Assay
• Microbial Culture

By End-user

• Biopharmaceutical
• CROs
• Cell Banks

By Product & Service

• Assays
• Kits
• Reagents

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa